<DOC>
	<DOCNO>NCT01294059</DOCNO>
	<brief_summary>Fibromyalgia syndrome ( FM ) share many symptom common chronic neuropathic pain , include characteristic hyperalgesia skin ( thermal , mechanical ) muscle ( mechanical ) find almost FM patient . Milnacipran , balance norepinephrine-serotonin re-uptake inhibitor , find reduce pain improve physical function FM patient . However , little known pain mechanism affect medication . Therefore , investigator want determine efficacy milnacipran reduce pain well mechanical thermal hyperalgesia FM patient randomize , double-blind , placebo control trial . Because investigator expect anti-hyperalgesic effect coincide precede effect clinical FM pain propose duration trial 6 week .</brief_summary>
	<brief_title>Effects Milnacipran Widespread Mechanical Thermal Hyperalgesia Fibromyalgia Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>1 . Patients diagnosis chronic widespread pain least 3 month , fulfill 1990 ACR Criteria FM . 2 . Patients mean pain rating â‰¥ 4.0 VAS unit , Screening Baseline visit . 3 . Patients , able comprehend satisfactorily comply protocol requirement . 4 . Patients take pain medication except acetaminophen within 3 day prior Baseline Visit ( medication take prior Screening Visit must discontinue Screening Visit Baseline Visit may schedule least 7 day past last dose medication ) . 5 . All woman childbearing potential ( WOCBP ) must negative urine pregnancy test Screening Visit . All woman childbearing potential participating study must use medically acceptable form contraception 1 . FM patient unwilling unable discontinue analgesic ( except Tylenol ) least 5 drug halflives prior enrollment . 2 . Patient previously fail treatment Milnacipran FM pain . 3 . Patients treat MAO inhibitor within 30 day prior Baseline Visit . 4 . Patients receive ECT within 3 month prior Screening Visit . 5 . Women pregnant nursing , woman childbearing potential use adequate contraception , judge unreliable use contraception . 6 . Patients participate clinical trial within one month prior Screening Visit . 7 . Patients medical condition , Investigator 's opinion , would expose increase risk significant adverse event interfere assessment safety efficacy course trial . 8 . Patients severe renal insufficiency ( Creatinine clearance &lt; 30 ml/min ) 9 . Patient BDI score &gt; 29 10 . Patients current malignancy , clinically significant hematological , endocrine , cardiovascular , renal , hepatic , gastrointestinal neurological disease ( include form epilepsy ) . If history disease condition stable least past year judge investigator interfere patient 's participation study , patient may include . 11 . Patients systolic blood pressure great 180 mm Hg le 90 mm Hg diastolic blood pressure great 105 mm Hg le 50 mm Hg Screening visit . Similarly , tachycardia &gt; 110/min exclusionary . 12 . Patients require concomitant therapy prohibit prescription overthecounter medication , include aspirin ( except 81 mg heart disease ) antidepressant medication . 13 . Patients unable speak , read , understand English judge investigator unable unlikely follow study protocol complete schedule visit .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Hyperalgesia</keyword>
	<keyword>Pain</keyword>
	<keyword>Central Sensitization</keyword>
</DOC>